Dosecann launched a precision-dosed cannabinoid product featuring Ahiflower and Lonza's Licaps Capsugel capsules for the Canadian medical cannabis space.
Dosecann (Toronto, Ontario) launched Dosecann Capsules, a precision-dosed cannabis product that combines broad-spectrum cannabinoids derived from a whole-plant cannabis resin with Ahiflower oil, which is rich in medium-chain triglycerides (MCT), and a plant-based source of omegas 3, 6, and 9. Each capsule delivers 25 mg of CBD, 1 mg of THC and 500 mg of Ahiflower oil, which includes 320 mg of omega-3, 85 mg of omega-6, and 51 mg of omega 9 oleic fatty acid.
“Our innovation team has thoroughly researched and rigorously tested Dosecann Capsules to ensure they are consistent with our guiding principles of quality, safety and efficacy,” said Bob Chapman, PhD, chief science officer, Dosecann, in a press release. “Balanced, omega-rich Ahiflower oil has proven to be an ideal carrier oil for Dosecann’s refined cannabis resins, which feature the full range of cannabinoids, terpenes, flavonoids and other phytonutrients found in the cannabis plant. The resulting capsule formulations offer all the natural qualities of the cannabis and Ahiflower plants in a convenient capsule format that wellness consumers are sure to love.”
The mixture of cannabinoids and Ahiflower oil is sealed in Lonza’s Licaps Capsugel capsules, which promote precise, standardized dosing, a longer shelf-life, and rapid digestion.